ClinicalTrials.gg
CompletedNCT01576029SWITCHUpdated Dec 24, 2013

Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer

A Phase 2 interventional study of CABAZITAXEL (XRP6258) and DOCETAXEL (XRP6976) in Prostatic Neoplasms, sponsored by Sanofi. Completed at 8 sites in Brazil. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-24.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
41st of 46
2 · median 60
Started
2012
with 5 others
Phase 2
28 of 46
5 open now
Registered
11th of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 41st largest by enrollment, is one of 6 that started in 2012, is one of 28 in phase 2, and was the 11th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To compare the continuation of treatment with docetaxel versus switching to cabazitaxel regarding the time to PSA (Prostatic Specific Antigen) progression (TTP-PSA), in patients with Castration-Resistant Prostate Cancer (CRPC) that, after four cycles of docetaxel, have minor PSA response (defined as a reduction between 1% and 49%) or increase of up to 24% in PSA levels.

Secondary Objectives:

  • PSA response rate
  • Overall survival (OS)
  • Incidence of Adverse Events
Read the detailed description

Screening: 21days (+7 days) Treatment: until PSA progression Post-treatment Follow-up: 2 years

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documentation of histological prostate cancer;
  • Patients with CRPC (Castration-Resistant Metastatic Prostate Cancer) who progressed with hormone deprivation, including the withdrawal of antiandrogen-class drugs for at least 4 weeks, and 6 weeks for bicalutamide or if documented that PSA did not decrease during 3 months of this therapy;
  • Documentation of metastasis by imaging (computerized tomography [CT], magnetic resonance imaging [MRI] or bone scan), in patients with PSA \< 20 ng/mL at the time of inclusion
  • Provide minor PSA response (characterized by a reduction between 1% and 49%) or increase up to 24% in PSA levels, in relation to the value measured before starting docetaxel therapy, measured at least 7 days after the fourth cycle of docetaxel;
  • Patient has received 4 cycles of docetaxel at a dose of 75 mg/m2 ;
  • performance status of 0 or 1;
  • Marrow, liver and renal function within acceptable values;
  • PSA ≥ 2 ng/mL;
  • Testosterone level ≤ 50 ng/dL (for patients with no prior history of orchiectomy).

Exclusion criteria

Exclusion criteria:

  • Prior use of chemotherapy, except for docetaxel for four cycles;
  • Documented disease progression during treatment with docetaxel (first 4 cycles);
  • Patients with resulting in neurological damage;
  • Inability to continue receiving gonadotropin-releasing hormone agonists in patients with no prior history of orchiectomy;
  • Use of recombinant methionyl human granulocyte-colony stimulating factor non-glycosylated (G-CSF) in the 24 hours preceding baseline;
  • Any other current neoplasia or over the past 5 years, except for basal cell skin carcinoma or squamous skin cell carcinoma;
  • Known seropositivity for (Human immunodeficiency Virus );
  • Concomitant diseases, such as significant neurological or psychiatric disease; uncontrolled hypercalcemia or any other serious comorbidity;
  • or allergy to any of the study treatments.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Active comparator
    Docetaxel

    75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks

    Drug: DOCETAXEL (XRP6976)

  • Experimental
    Cabazitaxel

    25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks

    Drug: CABAZITAXEL (XRP6258)

Interventions

06

What researchers measure

Primary outcomes

  1. Median time to PSA progression

    Time frame: up to 60 days

Secondary outcomes

  1. PSA response rate: Percentage of patients with a decrease of at least 50% in the PSA

    Time frame: up to 60 days

  2. Overall Survival: Median time elapsed between the date of starting treatment until death by any cause

    Time frame: up to a maximum of 2 years

  3. Number of patients with adverse events

    Time frame: up to a maximum of 2 years

07

Study locations

8 sites
  • Investigational Site Number 004
    Barretos, 14780-480, Brazil
  • Investigational Site Number 008
    Brasília, 70390-150, Brazil
  • Investigational Site Number 009
    Londrina, 86015-520, Brazil
  • Investigational Site Number 003
    Mogi das Cruzes, 0830-500, Brazil
  • Investigational Site Number 005
    Porto Alegre, 90840-440, Brazil
  • Investigational Site Number 006
    Rio De Janeiro, 20231-050, Brazil
  • Investigational Site Number 001
    Rio De Janeiro, 22260-020, Brazil
  • Investigational Site Number 007
    São Paulo, 01246-000, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2012
First posted
Apr 12, 2012
Start
Aug 2012
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Last update
Dec 24, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01576029
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 12, 2012
Start date
Aug 2012
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Dec 24, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion